ISCL/USCLC/EORTC global disease response score in primary cutaneous lymphomas
| Global score* . | Definition . | Skin . | Lymph nodes . | Viscera . | Blood . |
|---|---|---|---|---|---|
| CR | Complete disappearance of all clinical evidence of disease | CR | All categories involved at baseline have CR/NI | ||
| PR | Partial regression of measurable disease | CR | All categories involved do not have a CR/NI and no category has a PD | ||
| PR | No category has a PD and if any category involved at baseline, at least one has a PR or CR | ||||
| SD | Failure to attain CR, PR or PD representative of all disease | PR | No category has a PD and if any category involved at baseline, no CR or PR if any | ||
| SD | CR/NI, PR, SD in any category and no category has a PD | ||||
| PD | Progressive disease | PD in any category | |||
| Global score* . | Definition . | Skin . | Lymph nodes . | Viscera . | Blood . |
|---|---|---|---|---|---|
| CR | Complete disappearance of all clinical evidence of disease | CR | All categories involved at baseline have CR/NI | ||
| PR | Partial regression of measurable disease | CR | All categories involved do not have a CR/NI and no category has a PD | ||
| PR | No category has a PD and if any category involved at baseline, at least one has a PR or CR | ||||
| SD | Failure to attain CR, PR or PD representative of all disease | PR | No category has a PD and if any category involved at baseline, no CR or PR if any | ||
| SD | CR/NI, PR, SD in any category and no category has a PD | ||||
| PD | Progressive disease | PD in any category | |||
Modified from Olsen et al8 and Kempf et al.10 This table assumes that (1) all patients at baseline have measurable skin disease and (2) in patients with PCL and no extracutaneous disease at baseline, any new nodal or visceral involvement constitutes PD in those compartments.
NI, noninvolved; SD, stable disease.
This assumes that the response (CR, PR, SD, PD, or relapse) has been maintained for at least 4 weeks in any involved category.